Reaffirmed: Corcept Therapeutics (NASDAQ:CORT) “Hold” Rating Kept by Analysts at Stifel; $11 Target in Place

August 10, 2018 - By Christine McCrea

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo

Investors sentiment decreased to 1.28 in 2018 Q1. Its down 0.21, from 1.49 in 2017Q4. It fall, as 28 investors sold Corcept Therapeutics Incorporated shares while 55 reduced holdings. 46 funds opened positions while 60 raised stakes. 84.82 million shares or 2.95% less from 87.40 million shares in 2017Q4 were reported.

Northern Trust Corp, Illinois-based fund reported 1.12M shares. Convergence Inv Prtnrs Ltd Liability holds 0.24% of its portfolio in Corcept Therapeutics Incorporated (NASDAQ:CORT) for 110,861 shares. Navellier And Assoc accumulated 112,090 shares or 0.28% of the stock. The Pennsylvania-based Pnc Fincl Gru has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Vanguard Group invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Arizona State Retirement Systems has invested 0.02% in Corcept Therapeutics Incorporated (NASDAQ:CORT). Dana Investment Advisors Inc holds 0.09% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 122,868 shares. Evanson Asset Mngmt Lc accumulated 39,800 shares. State Board Of Administration Of Florida Retirement Systems accumulated 0% or 51,163 shares. Bridgeway Capital invested in 0.01% or 31,000 shares. Huntington National Bank owns 1,963 shares. 79,937 were reported by Kepos Cap Limited Partnership. D E Shaw And holds 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT) or 58,928 shares. Ls Advsrs Llc invested in 13,887 shares. Rafferty Asset Management Limited Liability Co invested 0.01% in Corcept Therapeutics Incorporated (NASDAQ:CORT).

Since March 6, 2018, it had 1 insider buy, and 6 insider sales for $988,257 activity. FISHMAN ROBERT S sold $125,323 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, March 7. On Tuesday, March 6 the insider GALA RENEE D bought $155,102.

Corcept Therapeutics (NASDAQ:CORT) Rating Reaffirmed

Recently, In a note sent to investors on Friday morning, Corcept Therapeutics (NASDAQ:CORT) shares have had their “Hold” Rating reconfirmed by equity analysts at Stifel, who currently has a $11 target price per share on firm. This target by Stifel indicates the possibile downside of -17.04 % from the current stock price.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 4 analysts covering Corcept Therapeutics Inc (NASDAQ:CORT), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Corcept Therapeutics Inc has $3200 highest and $3000 lowest target. $30.67’s average target is 131.30% above currents $13.26 stock price. Corcept Therapeutics Inc had 7 analyst reports since March 8, 2018 according to SRatingsIntel. As per Tuesday, June 19, the company rating was maintained by FBR Capital. The rating was maintained by FBR Capital with “Buy” on Tuesday, March 20. Seaport Global initiated Corcept Therapeutics Incorporated (NASDAQ:CORT) on Friday, April 13 with “Buy” rating. As per Tuesday, June 12, the company rating was maintained by FBR Capital. The firm has “Hold” rating given on Thursday, May 31 by Stifel Nicolaus. The firm earned “Buy” rating on Thursday, March 8 by FBR Capital.

The stock decreased 5.15% or $0.72 during the last trading session, reaching $13.26. About 4.06 million shares traded or 226.84% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has risen 60.38% since August 11, 2017 and is uptrending. It has outperformed by 47.81% the S&P500.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.53 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 11.73 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

More notable recent Corcept Therapeutics Incorporated (NASDAQ:CORT) news were published by: Streetinsider.com which released: “Pre-Open Movers 08/10: (MDLY) (OSTK) (TTD) Higher; (XONE) (CORT) (HAIR) Lower (more…)” on August 10, 2018, also Gurufocus.com with their article: “3 Stocks to Sell Friday” published on August 10, 2018, Benzinga.com published: “7 Stocks Moving In Thursday’s After-Hours Session” on August 09, 2018. More interesting news about Corcept Therapeutics Incorporated (NASDAQ:CORT) were released by: Nasdaq.com and their article: “Corcept Therapeutics Announces Second Quarter 2018 Financial Results and Stock Repurchase Program; Provides …” published on August 09, 2018 as well as Seekingalpha.com‘s news article titled: “Should You Buy Corcept Therapeutics Before Earnings?” with publication date: July 23, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.